News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Newron Pharmaceuticals Says Phase II Study Show Painkiller Ralfinamide Improves Quality of Life
July 17, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH (Thomson Financial) - Newron Pharmaceuticals SpA said its painkiller ralfinamide improved patients' quality of life compared to a placebo in phase II clinical tests.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Europe
MORE ON THIS TOPIC
Podcast
China Crackdown, UK Exit, Novo Layoffs, Adcomm Flip Flop, More
September 17, 2025
·
2 min read
·
Heather McKenzie
Obesity
Lilly Paints ‘Competitive Profile’ for Obesity Pill With Detailed Late-Stage Data
September 17, 2025
·
2 min read
·
Tristan Manalac
Artificial Intelligence
The Future of Pharma Is Predictive Care Powered by Consumers, AI: PwC
September 17, 2025
·
2 min read
·
Annalee Armstrong
Obesity
Novo’s Amylin Injectable Cagrilintide Hits 11.8% Weight Reduction in Phase III Trial
September 16, 2025
·
2 min read
·
Dan Samorodnitsky
